Uterine Fibroid Treatment Denied by Insurance? How to Appeal

Uterine fibroids affect up to 70–80% of women by age 50, and for many, they cause debilitating symptoms — heavy menstrual bleeding, pelvic pain, pressure, and even infertility. Despite being the most common benign uterine tumors in women, fibroid treatment is routinely denied, delayed, or restricted by insurance companies. Here's how to fight back.

Overview of Fibroid Treatment Options

Insurance denials often arise from disputes about which treatment is appropriate. Understanding the options helps frame your appeal:

• Watchful waiting: Appropriate for asymptomatic or minimally symptomatic fibroids
• Medical management: Hormonal therapy, GnRH agonists (Lupron), or the newer GnRH antagonists (Oriahnn, Myfembree)
• Uterine fibroid embolization (UFE): A minimally invasive interventional radiology procedure that shrinks fibroids by blocking their blood supply
• Focused ultrasound (MRgFUS): MRI-guided focused ultrasound that uses heat to destroy fibroid tissue without surgery
• Myomectomy: Surgical removal of fibroids while preserving the uterus
• Hysterectomy: Surgical removal of the uterus (definitive treatment)

ACOG and the Society of Interventional Radiology (SIR) endorse all of these as appropriate treatment options depending on the clinical situation. A patient's desire to preserve her uterus or fertility is a legitimate and recognized clinical consideration.

UFE Denied as "Experimental"

Uterine fibroid embolization is FDA-approved and has been performed for over 30 years. Clinical outcomes are well-established: UFE is as effective as hysterectomy for symptom relief in most patients and has a significantly faster recovery time.

Yet insurance companies still deny UFE by claiming it is "experimental" or "investigational." This denial is factually wrong. ACOG, SIR, and ACR all recognize UFE as an established, evidence-based treatment for symptomatic uterine fibroids. When appealing a UFE denial:

• Cite the Society of Interventional Radiology's practice guidelines for UFE
• Cite ACOG Practice Bulletin No. 96 (Alternatives to Hysterectomy in Management of Leiomyomas)
• Point out that UFE has FDA clearance and has been performed clinically since the 1990s
• Provide your interventional radiologist's letter documenting your candidacy for UFE

Myomectomy vs. Hysterectomy Step Therapy Disputes

A common insurer tactic: deny myomectomy (fibroid-preserving surgery) and require hysterectomy as the definitive covered treatment, or vice versa. Some insurers require documented failure of medical management before approving surgery.

The decision between myomectomy and hysterectomy is deeply personal and involves considerations of fertility, uterine preservation, and symptom burden. ACOG explicitly supports a patient's right to choose the least invasive, uterus-preserving treatment. Forcing a patient toward hysterectomy over myomectomy — or requiring failed medical therapy first when the patient has already failed or cannot tolerate hormonal treatment — is not consistent with clinical guidelines.

In your appeal, emphasize:

• Your stated desire to preserve your uterus (or maintain fertility)
• Prior failure of medical management, if applicable
• ACOG guidelines supporting myomectomy as a legitimate, guideline-endorsed option
• Your surgeon's specific recommendation and the clinical rationale

MRI-Guided Focused Ultrasound (MRgFUS) Denials

MRgFUS (Exablate Neuro or ExAblate Body system) is FDA-approved for treating symptomatic uterine fibroids. It is noninvasive and has excellent patient outcomes for appropriately selected patients.

Despite FDA approval, many insurers still classify MRgFUS as "experimental" or refuse to cover it as "not medically necessary when surgical alternatives exist." These denials are increasingly indefensible.

Appeal using:

• FDA clearance documentation for ExAblate Body for uterine fibroids
• ACOG recognition of focused ultrasound as an approved treatment modality
• Your specific clinical suitability for MRgFUS (documented by your MFM or gynecologist)
• The clinical benefits of noninvasive treatment versus surgical risk

GnRH Antagonist Prior Authorization Denied: How to Appeal" class="auto-link">Prior Authorization Denials

Newer oral GnRH antagonists — Oriahnn (elagolix/estradiol/norethindrone) and Myfembree (relugolix/estradiol/norethindrone) — are FDA-approved for managing heavy menstrual bleeding from uterine fibroids. They are on-label treatments, not experimental.

Insurers frequently require step therapy through older GnRH agonists (Lupron) before approving these newer agents, or require prior authorization with extensive documentation. If you have tried and failed Lupron or GnRH agonists, or have a clinical reason you cannot use them (e.g., bone density concerns, menopausal symptom intolerability), document these reasons thoroughly in a prior authorization appeal.

How to Appeal a Fibroid Treatment Denial

Step 1: Identify the specific reason for denial. Is it "experimental," "not medically necessary," or a step-therapy requirement?

Step 2: Get a detailed letter from your treating physician. Your gynecologist or interventional radiologist should explain why the requested treatment is the appropriate choice for your specific situation and document prior treatments tried.

Step 3: Cite clinical guidelines. ACOG Practice Bulletin No. 96, SIR UFE guidelines, and ACR Appropriateness Criteria are powerful, credible sources.

Step 4: File your internal appeal within 180 days. Include all documentation.

Step 5: Request External Independent Review: Complete Guide" class="auto-link">external review. External reviewers with gynecology expertise regularly overturn "experimental" denials for established procedures like UFE and MRgFUS.

Fight Back With ClaimBack

Don't let your insurer dictate your fibroid treatment options. ClaimBack generates a compelling, evidence-based appeal letter that takes on "experimental" denials head-on with the clinical evidence they ignore.

Start your free appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: What's the Difference?